HomeCAMX • STO
Camurus AB
kr 573.00
Nov 22, 6:00:00 PM GMT+1 · SEK · STO · Disclaimer
StockSE listed security
Previous close
kr 561.00
Day range
kr 562.50 - kr 574.00
Year range
kr 417.40 - kr 715.00
Market cap
33.70B SEK
Avg Volume
83.14K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
(SEK)Sep 2024Y/Y change
Revenue
479.60M24.90%
Operating expense
304.26M22.71%
Net income
129.35M49.72%
Net profit margin
26.9719.87%
Earnings per share
2.1644.00%
EBITDA
145.52M35.34%
Effective tax rate
21.75%
Total assets
Total liabilities
(SEK)Sep 2024Y/Y change
Cash and short-term investments
2.75B138.44%
Total assets
3.57B93.65%
Total liabilities
454.20M28.54%
Total equity
3.11B
Shares outstanding
58.81M
Price to book
10.60
Return on assets
10.13%
Return on capital
11.66%
Net change in cash
(SEK)Sep 2024Y/Y change
Net income
129.35M49.72%
Cash from operations
149.66M-69.19%
Cash from investing
-5.93M-338.54%
Cash from financing
42.49M151.02%
Net change in cash
184.14M-63.16%
Free cash flow
62.81M-85.82%
About
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
Founded
1991
Employees
225
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu